Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Tirzepatide may be more effective than semaglutide in helping people lose weight. At least that's the findings from recent ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA first announced two months ago that any shortage of the medications ...

Participants taking tirzepatide also lost more body weight than those taking glucagon-like peptide-1 (GLP-1) receptor ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...

But, Krumholz noted, the newer GLP-1 drugs, which are given as weekly ... which use the active ingredient tirzepatide. They can cost $1,000 a month or more without insurance or discounts.